For patients with metastatic cancer, a systemic treatment is recommended after testing for the expression of human epidermal growth factor receptor-2 (HER-2) in order to check whether trastuzumab should be added to well-established chemotherapeutic regimens [106]. Here, ERBB2 is linked to metastatic malignant neoplasm.